Compare CCG & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCG | ELUT |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | 469 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 48.3M |
| IPO Year | N/A | 2020 |
| Metric | CCG | ELUT |
|---|---|---|
| Price | $0.47 | $0.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $350.00 | $6.00 |
| AVG Volume (30 Days) | ★ 145.2K | 103.1K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $567.38 | $10.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.47 | $0.50 |
| 52 Week High | $1.54 | $2.60 |
| Indicator | CCG | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 42.56 |
| Support Level | N/A | $0.86 |
| Resistance Level | $0.77 | $0.99 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 2.32 | 13.97 |
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services, and other services in China. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.